Survival in Skyscraper-01 deteriorated, and bore no relation to the Cityscape result.
ApexOnco Front Page
Recent articles
A BNT327 and BNT325 combo shows promise in platinum-resistant ovarian cancer.
But sasanlimab's use looks set to remain narrow.
But the company is awaiting pivotal results with TAR-200 in papillary disease before filing.
Skyscraper-07 fails, while a Poseida-originated Car-T is also scrapped.
The curtain lifts on Veritac-2, rusfertide, and another double plenary for Astra.
Can activity at CTLA-4 be added to PD-1 x VEGF blockade?
The PD-1 x VEGF molecule's latest win comes from Akeso's Harmoni-6 trial.
